To independently confirm these findings, we carried out the converse set of experiments, namely restoring SMARCA4 expression in SMARCA4-deficient pancreatic cancer cells, and evaluating altered chemo sensitivities. This evidence concerns the gene SMARCA4 and pancreatic neoplasm.